## **Activation of protein kinase C by tyrosine phosphorylation in response to**  $H_2O_2$

HIROAKI KONISHI\*, MOTONARI TANAKA†, YUKITOSHI TAKEMURA†, HIDENORI MATSUZAKI†, YOSHITAKA ONO†, USHIO KIKKAWA\*‡, AND YASUTOMI NISHIZUKA\*

\*Biosignal Research Center, Kobe University, and †Department of Biology, Faculty of Science, Kobe University, Kobe 657, Japan

*Contributed by Yasutomi Nishizuka, August 11, 1997*

**ABSTRACT** Protein kinase C (PKC) isoforms,  $\alpha$ ,  $\beta$ I, and  $\gamma$  of cPKC subgroup,  $\delta$  and  $\epsilon$  of nPKC subgroup, and  $\zeta$  of **aPKC subgroup, were tyrosine phosphorylated in COS-7 cells** in response to  $H_2O_2$ . These isoforms isolated from the  $H_2O_2$ **treated cells showed enhanced enzyme activity to various** extents. The enzymes, PKC  $\alpha$  and  $\delta$ , recovered from the cells **were independent of lipid cofactors for their catalytic activity.** Analysis of mutated molecules of PKC  $\delta$  showed that tyrosine **residues, which are conserved in the catalytic domain of the** PKC family, are critical for PKC activation induced by H<sub>2</sub>O<sub>2</sub>. **These results suggest that PKC isoforms can be activated through tyrosine phosphorylation in a manner unrelated to receptor-coupled hydrolysis of inositol phospholipids.**

Protein kinase C (PKC) is activated by 1,2-diacylglycerol produced from receptor-mediated hydrolysis of inositol phospholipids (1). PKC comprises a large family of multiple isoforms with regulatory and catalytic domains in the aminoand carboxyl-terminal halves, respectively. The isoforms are divided into three subgroups, cPKC, nPKC, and aPKC, due to the structural differences in their regulatory domains. Among PKC isoforms, PKC  $\delta$  has been shown to be phosphorylated on tyrosine in v-*ras*-transformed keratinocytes (2) and in various cells stimulated with mitogens such as phorbol ester and growth factors (3–6). PKC  $\delta$  has also reported to be phosphorylated *in vitro* by various tyrosine kinases such as Fyn (3,  $(6, 7)$ , c-Src  $(6-8)$ , and growth factor receptors  $(3, 6)$ . Thus far, Tyr<sup>52</sup> (9) and Tyr<sup>187</sup> (10) in its amino-terminal half have been identified as the phosphorylation sites. The functional consequence of this reaction, however, remains controversial; the tyrosine phosphorylation reduces its phorbol ester-dependent catalytic activity in some cells (2, 6), whereas the reaction enhances the enzyme activity in some other cells (3). On the other hand, oxidative stress has been reported to induce prolonged activation of PKC within the cells (11–14). It was postulated that oxidative modification, which occurs probably in the regulatory domain, may generate active enzyme (14), but no evidence is available for such modification. Here, we report that, upon treatment of cells with  $H_2O_2$ , all PKC isoforms examined, including  $\alpha$ ,  $\beta$ I, and  $\gamma$  of cPKC,  $\delta$  and  $\epsilon$  of nPKC, and  $\zeta$  of aPKC, are tyrosine phosphorylated and catalytically activated, and that tyrosine residues in the catalytic domain are crucial for activation of these enzymes.

## **MATERIALS AND METHODS**

**Expression Plasmids.** Hemagglutinin (HA)-epitope-tagged expression plasmids of PKC isoforms were constructed as described (15). Plasmid pTB801 was employed as an expression plasmid of PKC  $\delta$  without epitope tag (16). Lys<sup>376</sup> of PKC  $\delta$  was replaced with methionine by site-directed mutagenesis to make HA-epitope-tagged kinase-negative PKC  $\delta$  (17). FLAGepitope-tagged expression plasmids of PKC  $\delta$  were constructed by using pECE vector (17). Tyr<sup>451</sup>, Tyr<sup>469</sup>, Tyr<sup>512</sup>, and Tyr $523$  of PKC  $\delta$  were replaced with phenylalanine by sitedirected mutagenesis. The DNA sequences of these constructs were confirmed by the dideoxynucleotide chain-termination method using a DNA Sequencing System model 373A (Applied Biosystems).

**Cells and Transfection.** COS-7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum at 37°C in a 5%  $CO<sub>2</sub>/95%$  air incubator. Cells were transfected with the expression plasmids by electroporation, cultured for 48 h (17), and treated as described in each experiment.

**Immunoprecipitation.** All procedures were carried out at 0–4°C as described (17). Cells were washed with phosphatebuffered saline and lysed in 20 mM Tris·HCl at pH 7.5 containing 1 mM EDTA, 1 mM EGTA, 10 mM 2 mercaptoethanol, 1% Triton X-100, 150 mM NaCl, 10 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, and 50  $\mu$ g/ml phenylmethylsulfonyl fluoride. The lysate was centrifuged for 10 min at  $18,000 \times g$ , and the supernatant was incubated for 1 h with an anti-HA monoclonal antibody (Boehringer Mannheim), a polyclonal antibody against PKC  $\delta$  (Transduction Laboratories, Lexington, KY), or an anti-FLAG monoclonal antibody (Kodak Scientific Imaging Systems). Then, protein A-Sepharose beads (Pharmacia) were added to the mixture and incubated for 30 min. The immunoprecipitates were collected by centrifugation and washed four times with 20 mM Tris·HCl at pH 7.5 containing 150 mM NaCl and 1% Triton X-100.

**Immunoblot Analysis.** The immunoprecipitates were boiled in SDS sample buffer, and proteins were separated by SDS/ PAGE and transferred onto an Immobilon P membrane (Millipore). Immunoblot analysis was carried out using the anti-HA antibody, the anti-FLAG antibody, a monoclonal anti-phosphotyrosine antibody (4G10; Upstate Biotechnology, Lake Placid, NY), or an antibody against the carboxyl-terminal region of PKC  $\delta$  (GIBCO/BRL) as the first antibody, and alkaline phosphatase-conjugated second antibodies (Promega) as described (17).

**Metabolic Labeling.** Transfected cells were cultured for 1 h in phosphate-free DMEM supplemented with dialyzed fetal calf serum, and then metabolically labeled for 3 h with  $[32P]$ orthophosphate (18 MBq/6-cm dish). PKC was then immunoprecipitated and was separated by SDS/PAGE, and phosphoamino acid analysis was carried out as described (18). The radioactive phosphoproteins and phosphoamino acids were visualized by a Bio-Imaging Analyzer (Fuji).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''*advertisement*'' in accordance with 18 U.S.C. §1734 solely to indicate this fact.

<sup>© 1997</sup> by The National Academy of Sciences 0027-8424/97/9411233-5\$2.00/0 PNAS is available online at http://www.pnas.org.

Abbreviations: PKC, protein kinase C; HA, hemagglutinin; PSL, photostimulated luminescence.

<sup>‡</sup>To whom reprint requests should be addressed at: Biosignal Research Center, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe 657 Japan. e-mail: ukikkawa@inherit.biosig.kobe-u.ac.jp.



FIG. 1. Tyrosine phosphorylation of PKC isoforms in transfected COS-7 cells exposed to H2O2. (*A*) Tyrosine phosphorylation of PKC isoforms. Cells transfected with each HA-epitope-tagged PKC expression plasmid were incubated with 5 mM  $H_2O_2$  for 10 min, and PKC isoforms were immunoprecipitated (IP) by the anti-HA antibody. Immunoblot analysis was carried out using the anti-HA antibody (*Upper*) or the antiphosphotyrosine antibody (anti-PY) (*Lower*). Positions of PKC isoforms and IgG are indicated by open and closed arrows, respectively. (*B*) Phosphorylation of PKC  $\delta$ . Cells transfected with the expression plasmid of PKC  $\delta$  without epitope tag were labeled metabolically with [<sup>32</sup>P]orthophosphate and incubated with 5 mM H<sub>2</sub>O<sub>2</sub> for 10 min. PKC  $\delta$  was immunoprecipitated by the antibody against PKC  $\delta$ . The phosphorylated PKC  $\delta$  was visualized by a Bio-Imaging Analyzer. The position of PKC  $\delta$  is indicated by an open arrow. (C) Phosphoamino acid analysis of PKC <sup>d</sup>. The phosphorylated PKC <sup>d</sup> recovered form the gel in *B* was subjected to phosphoamino acid analysis. Positions of phosphoserine (P-Ser), phosphothreonine (P-Thr), and phosphotyrosine (P-Tyr) are indicated by arrowheads.

**Protein Kinase Assay.** PKC activity was assayed by measuring the incorporation of  ${}^{32}P_1$  into calf thymus H1 histone from  $[\gamma^{32}P]ATP$  in the reaction mixture containing 20 mM Tris•HCl at pH 7.5, 10 mM MgCl<sub>2</sub>, 20  $\mu$ M ATP, 15–50 kBq of  $[\gamma^{32}P]ATP$ , and 200  $\mu$ g/ml H1 histone (16, 17). The incubation was carried out for 5 min at 30°C, and the phosphorylated proteins were separated by SDS/PAGE and visualized and quantitated by measuring the intensity of photostimulated luminescence (PSL) using a Bio-Imaging Analyzer. Where indicated, PKC activity was measured in the presence of 8  $\mu$ g/ml phosphatidylserine, 0.8  $\mu$ g/ml diacylglycerol, or 0.5 mM  $CaCl<sub>2</sub>$ .

**One-Dimensional Peptide Mapping.** FLAG-epitope-tagged PKC  $\delta$  (approximately 0.5  $\mu$ g) was purified from the H<sub>2</sub>O<sub>2</sub>treated COS-7 cells by FLAG M2 affinity gel column chromatography (19). The enzyme was digested partially with tosylphenylalanine chloromethyl ketone (TPCK)-treated tryp- $\sin(0.4 \text{ pmol})$  at 30 $\degree$ C for the indicated time in 20 mM Tris $\degree$ HCl at pH 7.5 containing 0.5 mM EDTA, 0.5 mM EGTA, and 10 mM 2-mercaptoethanol. The digested samples were subjected to immunoblot analysis.

## **RESULTS**

Tyrosine Phosphorylation of PKC in Cells Exposed to H<sub>2</sub>O<sub>2</sub>. When COS-7 cells that were transfected with epitope-tagged PKC isoform of  $\alpha$ ,  $\beta I$ ,  $\gamma$ ,  $\delta$ ,  $\varepsilon$ , or  $\zeta$  were stimulated with H<sub>2</sub>O<sub>2</sub>, all PKC isoforms were tyrosine phosphorylated as judged by immunoblot analysis (Fig. 1A). <sup>32</sup>P-Tracer experiment with PKC  $\delta$ , for example, showed that  $H_2O_2$  enhances phosphorylation of this isoform (Fig. 1*B*). Phosphoamino acid analysis revealed that tyrosine residue as well as serine and threonine



FIG. 2. Activation of PKC isoforms by H<sub>2</sub>O<sub>2</sub> in transfected COS-7 cells. Cells transfected with each HA-epitope-tagged PKC expression plasmid were incubated with 5 mM H<sub>2</sub>O<sub>2</sub> for the indicated time. PKC isoforms were immunoprecipitated by the anti-HA antibody, and PKC activity was assayed with H1 histone as substrate. Phosphorylated proteins were separated by SDSyPAGE and visualized by using a Bio-Imaging Analyzer.

Table 1. PKC activity in transfected COS-7 cells treated with  $H_2O_2$ 

PKC isoform	$H2O2$ treatment, min	PKC activity	
		<b>PSL</b>	%
$\alpha$	0	20,300	100
$\alpha$	5	33,500	165
$\alpha$	10	54,600	269
βI	$\overline{0}$	24,200	100
βI	5	35,600	147
βI	10	56,900	235
$\gamma$	$\theta$	22,700	100
$\gamma$	5	46,100	203
$\gamma$	10	65,500	289
$\delta$	0	9,240	100
$\delta$	5	49,200	532
δ	10	42,000	455
ε	0	10,400	100
ε	5	34,000	327
ε	10	46,800	450
ζ	$\theta$	14,100	100
ζ	5	53,000	376
ζ	10	67,100	476

Phosphorylation of H1 histone by PKC isoforms described in Fig. 2 was quantitated by measuring PSL using a Bio-Imaging Analyzer. The activity of each PKC isoform recovered from the cells without  $H_2O_2$ treatment was used as 100%.

residues are indeed phosphorylated in response to  $H_2O_2$  (Fig. 1*C*).

Activation of PKC in Cells Exposed to H<sub>2</sub>O<sub>2</sub>. PKC isoforms obtained from the  $H_2O_2$ -treated cells were assayed for their enzyme activity with H1 histone as substrate (Fig. 2). The results showed that PKC  $\delta$ ,  $\varepsilon$ , and  $\zeta$  are activated severalfold and that PKC  $\alpha$ ,  $\beta$ I, and  $\gamma$  are stimulated to lesser extent (Table 1). Autophosphorylation of these PKC isoforms was also enhanced (Fig. 2). Menadione, which generates superoxide anion, also induced tyrosine phosphorylation as well as activation of PKC isoforms (data not shown).

Next, catalytic properties of tyrosine-phosphorylated PKC isoforms were studied (Fig. 3). In response to  $H_2O_2$ , a kinase-

Table 2. Properties of PKC isoforms recovered from the H2O2-treated cells

<b>PKC</b>	$H_2O_2$ treatment,			PKC activity	
isoform	min	Activators	PSL	%	
δ	0		9,100	100	
δ	0	PS, DG	37,400	441	
δ	10		41,900	460	
δ	10	PS, DG	40,600	446	
$\alpha$	0		20,500	100	
$\alpha$	0	PS, DG, $Ca^{2+}$	133,000	650	
$\alpha$	10		86,100	420	
$\alpha$	10	PS, DG, $Ca^{2+}$	80,000	390	

Phosphorylation of H1 histone by the PKC isoforms described in Fig. 3 in the presence or absence of phosphatidylserine (PS), diacylglycerol (DG), and Ca<sup>2+</sup> was quantitated by measuring PSL using a Bio-Imaging Analyzer. The activity of each PKC isoform recovered from the cells without  $H_2O_2$  treatment in the absence of these activators was used as 100%.

negative mutant of PKC  $\delta$  was tyrosine phosphorylated as well (Fig. 3*A*), although it did not show any enzyme activity either before or after  $H_2O_2$  stimulation (Fig. 3*B*). Thus, the protein kinase activity measured in this experiment represents PKC  $\delta$ itself, but is not due to any other protein kinases that might contaminate the immunoprecipitates. It is worth noting that PKC  $\delta$  obtained from the H<sub>2</sub>O<sub>2</sub>-treated cells was not activated by phosphatidylserine and diacylglycerol, whereas the enzyme from the untreated cells required these lipids for enzyme activity (Fig. 3*B*). Similarly, PKC  $\alpha$  prepared from the H<sub>2</sub>O<sub>2</sub>treated cells did not require  $Ca^{2+}$ , phosphatidylserine, or diacylglycerol (Fig. 3*C*). The results are given quantitatively in Table 2. It was concluded that PKC isoforms phosphorylated on tyrosine are almost fully active without  $Ca^{2+}$  and lipid activators. The stoichiometry of tyrosine phosphorylation is unknown, but PKC isoforms recovered form the  $H_2O_2$ -treated cells seem to be phosphorylated on at least one tyrosine residue, because the enzyme was almost quantitatively trapped by an anti-phosphotyrosine agarose column (data not shown). H2O2-induced tyrosine phosphorylation and activation of the PKC isoforms were observed also for NIH 3T3 cells, which



FIG. 3. Properties of tyrosine-phosphorylated PKC recovered from transfected COS-7 cells. (A) Expression of PKC  $\delta$  and kinase-negative PKC  $\delta$ . Cells transfected with HA-epitope-tagged plasmid of either PKC  $\delta$  or kinase-negative PKC  $\delta$  ( $\delta$ KN) were incubated with 5 mM H<sub>2</sub>O<sub>2</sub> for 10 min. The expressed proteins were immunoprecipitated by the anti-HA antibody. Immunoblot analysis was carried out using the anti-HA antibody (*Upper*) or the anti-phosphotyrosine antibody (*Lower*). Positions of PKC <sup>d</sup> and IgG are indicated by open and closed arrows, respectively. (*B*) Protein kinase assay of PKC  $\delta$ . Protein kinase activity of the immunoprecipitates recovered in *A* was assayed with H1 histone as substrate in the presence or absence of 8  $\mu$ g/ml phosphatidylserine (PS) and 0.8  $\mu$ g/ml diacylglycerol (DG). (*C*) Protein kinase assay of PKC  $\alpha$ . HA-epitope-tagged PKC  $\alpha$  was expressed, immunoprecipitated as in *A*, and assayed as in *B* in the presence of 0.5 mM Ca<sup>2+</sup>, phosphatidylserine, and diacylglycerol.

were employed as host cells instead of COS-7 cells (data not shown).

**Tyrosine Phosphorylation Sites in PKC Induced by H2O2 Treatment.** Tyr<sup>52</sup>(9) and Tyr<sup>187</sup>(10) in the amino-terminal half of PKC  $\delta$  were previously shown to be phosphorylated. Mutated molecules of PKC  $\delta$  deleting the amino-terminal region, including these two tyrosine residues, were still phosphorylated on tyrosine in response to  $H_2O_2$  (data not shown). The molecule of PKC  $\delta$  recovered from the H<sub>2</sub>O<sub>2</sub>-treated cells was digested partially with trypsin and subjected to immunoblot analysis to explore the region of tyrosine phosphorylation (Fig. 4*A*). Tryptic fragments with approximate molecular mass of 25 and 45 kDa were detected by the antibody against phosphotyrosine as well as the antibody recognizing the carboxyl terminus of PKC  $\delta$ , but not by the antibody against the epitope tag linked to the amino terminus of the enzyme. The results indicated that PKC  $\delta$  is phosphorylated on tyrosine in its carboxyl-terminal half region including the catalytic domain.

Because all PKC isoforms examined were phosphorylated on tyrosine, we focused our attention on the tyrosine residues commonly present in the carboxyl-terminal half of the PKC family. Four tyrosine residues, Tyr<sup>451</sup>, Tyr<sup>469</sup>, Tyr<sup>512</sup>, and Tyr<sup>523</sup> of PKC  $\delta$ , are conserved in the carboxyl-terminal half of the PKC family (Fig. 4*B*) (1). Thus, each of these tyrosine residues was replaced by phenylalanine, and the mutated molecules were expressed in COS-7 cells (Fig. 4*C*). The replacement of either  $Tyr^{512}$  or Tyr<sup>523</sup> in subdomain VIII by phenylalanine attenuated  $H_2O_2$ -induced activation of the enzyme. The mutation of both  $Tyr^{512}$  and  $Tyr^{523}$  almost abolished enzyme activation, but the mutated enzyme was still tyrosine phosphorylated to some extent in response to  $H_2O_2$ . On the other hand, PKC  $\delta$  mutated on Tyr<sup>451</sup> or Tyr<sup>469</sup> in subdomains VIa and VIb was fairly activated and tyrosine phosphorylated. We conclude, therefore, that PKC  $\delta$  is phosphorylated on more than one tyrosine residue upon treatment with  $H_2O_2$  and that the tyrosine residues, especially  $Tyr^{512}$  and  $Tyr^{523}$  in subdomain VIII, are critical for PKC activation.

## **DISCUSSION**

It has been described that  $H_2O_2$  induces inositol phospholipid hydrolysis in some cultured cells (20, 21). In general, however, oxidative stress does not appear to produce diacylglycerol. It has also been postulated that  $H_2O_2$  induces oxidative modification of PKC, thereby activating the enzyme (14), but no substantial evidence is available for such modification. The present study indicates that all PKC isoforms examined are tyrosine phosphorylated and exhibit enhanced enzyme activity in response to  $H_2O_2$ . Tyrosine kinases such as Lck and Syk are known to be activated by oxidative stress (22–24). Some PKC isoforms were tyrosine phosphorylated *in vitro* by Lck and Syk, and in fact, the phosphorylated isoforms showed enzyme activity higher than the nonphosphorylated isoforms (data not shown). In addition to PKC  $\delta$ , PKC  $\alpha$  has been reported to be tyrosine phosphorylated in insulin-stimulated cells (25). However, the tyrosine kinases that phosphorylate PKC isoforms *in vivo* remain to be identified. Both PKB (26) and PKN (27) have a catalytic domain highly homologous to the PKC family, but were not tyrosine phosphorylated *in vitro* or in the  $H_2O_2$ treated cells (data not shown). Thus, phosphorylation on tyrosine does not appear to be a mechanism of activation commonly observed for protein kinases related to the PKC family.

For PKC  $\delta$ , tyrosine phosphorylation in subdomain VIII is critical for activation in response to  $H_2O_2$ . The significance of phosphorylation on serine and threonine residues concurrently observed in response to  $H_2O_2$  (Fig. 1*C*) was not investigated in the present study. It is possible that the PKC enzyme activated in the  $H<sub>2</sub>O<sub>2</sub>$ -treated cells autophosphorylates its serine and threonine residues. However, it cannot be ruled out



FIG. 4. Tyrosine phosphorylation sites in PKC. (*A*) Onedimensional peptide mapping analysis by partial proteolysis with trypsin. FLAG-epitope-tagged PKC  $\delta$  purified from the H<sub>2</sub>O<sub>2</sub>-treated cells was digested with trypsin for the indicated times. Immunoblot analysis was carried out using either the antibody against the carboxylterminal region of PKC  $\delta$  (anti-CT) (*Left*), the anti-phosphotyrosine antibody (anti-PY) (*Center*), or the anti-FLAG antibody [anti-FLAG(NT)] (*Right*). Positions of FLAG-epitope-tagged PKC  $\delta$  and of tyrosine-phosphorylated fragments are indicated by closed and open arrows, respectively. Molecular mass markers are shown in kDa. (*B*) Structure and phosphorylation sites of PKC  $\delta$ . The structure of PKC  $\delta$  is schematically shown, and amino acid sequences of subdomain VIa, VIb, and VIII of rat PKC isoforms are aligned. Two phosphorylation sites identified in the regulatory domain of PKC  $\delta$ , Tyr<sup>52</sup> and Tyr<sup>187</sup>, are indicated as 52Y and 187Y. The tyrosine residues conserved in the carboxyl-terminal half of the PKC family are highlighted. (*C*) Sitedirected mutagenesis of PKC  $\delta$ . COS-7 cells transfected with the expression plasmid of FLAG-epitope-tagged PKC  $\delta$  or with mutated molecules replacing tyrosine by phenylalanine were incubated with 5 mM H2O2 for 10 min, and FLAG-epitope-tagged molecules were immunoprecipitated. The mutants replacing Tyr<sup>451</sup>, Tyr<sup>469</sup>, Tyr<sup>512</sup>, Tyr<sup>523</sup>, and Tyr<sup>512</sup>/Tyr<sup>523</sup> were designated as Y451F, Y469F, Y512F, Y523F, and Y512/523F, respectively. Immunoblot analysis was carried out using either the anti-FLAG antibody (anti-FLAG) (*Top*) or the anti-phosphotyrosine antibody (anti-PY) (*Middle*). PKC activity in the immunoprecipitates was assayed with H1 histone as substrate (*Bottom*).

that some other serine and threonine protein kinases take part in PKC activation. Thr<sup>500</sup> in subdomain VIII of PKC  $\beta$  has been shown to be phosphorylated nearly stoichiometrically *in vivo* (28, 29). If Thr<sup>505</sup> in PKC  $\delta$ , which is equivalent to Thr<sup>500</sup> in

PKC  $\beta$ , is constitutively phosphorylated, PKC  $\delta$  could be phosphorylated on both threonine and tyrosine residues in subdomain VIII upon  $H_2O_2$  stimulation. Note that mitogenactivated protein kinases are phosphorylated for their activation dually on both threonine and tyrosine residues in subdomain VIII on the activation loop (30). Recently, however, it was reported that phosphorylation of Thr<sup>505</sup> in PKC  $\delta$  is not a prerequisite for its enzyme activity (31). More detailed studies are needed to understand fully the activation mechanisms of the PKC family involving protein phosphorylation.

Platelet-derived growth factor may generate  $H_2O_2$ , and  $H_2O_2$  is required for signaling of growth factors in some cultured cells (32). An obvious possibility arises that PKC can be activated in two independent signaling pathways in response to growth factors. One is the classical diacylglycerol-dependent pathway through activation of phospholipases C and D (1). The other could be a pathway through direct phosphorylation on tyrosine in subdomain VIII. Transcription factors NF-kB and AP-1 have been reported to be activated in two different ways: one is through PKC, and the other is by  $H_2O_2$  in a manner independent of PKC (33, 34). The results described herein suggest that  $H_2O_2$  could activate these transcription factors through activation of PKC involving tyrosine phosphorylation. The physiological picture of PKC activation by tyrosine phosphorylation will be substantiated by further investigations.

We thank Drs. R. M. Perlmutter and Y. Minami for providing the Lck cDNA, Dr. H. Yamamura for providing the Syk cDNA, and Ms M. Inagaki for secretarial assistance. This study was supported in part by research grants from the Scientific Research Funds of the Ministry of Education, Science, Sports and Culture of Japan, the Sankyo Research Institute for Neurosciences, and the Suntory Institute for Bioorganic Research.

- 1. Nishizuka, Y. (1995) *FASEB J.* **9,** 486–496.
- 2. Denning, M. F., Dlugosz, A. A., Howett, M. K. & Yuspa, S. H. (1993) *J. Biol. Chem.* **268,** 26079–26081.
- 3. Li, W., Mischak, H., Yu, J.-C., Wang, L.-M., Mushinski, J. F., Heidaran, M. A. & Pierce, J. H. (1994) *J. Biol. Chem.* **269,** 2349–2352.
- 4. Haleen-Smith, H., Chang, E.-Y., Szallasi, Z., Blumberg, P. M. & Rivera, J. (1995) *Proc. Natl. Acad. Sci. USA* **92,** 9112–9116.
- 5. Soltoff, S. P. & Toker, A. (1995) *J. Biol. Chem.* **270,** 13490–13495. 6. Denning, M. F., Dlugosz, A. A., Threadgill, D. W., Magnuson, T.
- & Yuspa, S. H. (1996) *J. Biol. Chem.* **271,** 5325–5331. 7. Gschwendt, M., Kielbassa, K., Kittstein, W. & Marks, F. (1994)
- *FEBS Lett.* **347,** 85–89.
- 8. Zang, Q., Lu, Z. M., Curto, M., Barile, N., Shalloway, D. & Foster, D. A. (1997) *J. Biol. Chem.* **272,** 13275–13280.
- Szallasi, Z., Denning, M. F., Chang, E.-Y., Rivera, J., Yuspa, S. H., Lehel, C., Olah, Z., Anderson, W. B. & Blumberg, P. M. (1995) *Biochem. Biophys. Res. Commun.* **214,** 888–894.
- 10. Li, W., Chen, X.-H., Kelley, C. A., Alimandi, M., Zhang, J., Chen, Q., Bottaro, D. P. & Pierce, J. H. (1996) *J. Biol. Chem.* **271,** 26404–26409.
- 11. Palumbo, E. J., Sweatt, D., Chen, S.-J. & Klann, E. (1992) *Biochem. Biophys. Res. Commun.* **187,** 1439–1445.
- 12. Brawn, M. K., Chiou, W. J. & Leach, K. L. (1995) *Free Radical Res.* **22,** 23–37.
- 13. Whisler, R. L., Goyette, M. A., Grants, I. S. & Newhouse, Y. G. (1995) *Arch. Biochem. Biophys.* **319,** 23–35.
- 14. Gopalakrishna, R. & Anderson, W. B. (1989) *Proc. Natl. Acad. Sci. USA* **86,** 6758–6762.
- 15. Kuroda, S., Tokunaga, C., Kiyohara, Y., Higuchi, O., Konishi, H., Mizuno, K., Gill, G. N. & Kikkawa, U. (1996) *J. Biol. Chem.* **271,** 31029–31032.
- 16. Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K. & Nishizuka, Y. (1988) *J. Biol. Chem.* **263,** 6927–6932.
- 17. Konishi, H., Matsuzaki, H., Tanaka, M., Ono, Y., Tokunaga, C., Kuroda, S. & Kikkawa, U. (1996) *Proc. Natl. Acad. Sci. USA* **93,** 7639–7643.
- 18. Boyle, W. J., van der Geer, P. & Hunter, T. (1991) *Methods Enzymol.* **201,** 110–149.
- 19. Matsuzaki, H., Konishi, H., Tanaka, M., Ono, Y., Takenawa, T., Watanabe, Y., Ozaki, S., Kuroda, S. & Kikkawa, U. (1996) *FEBS Lett.* **396,** 305–308.
- 20. Shasby, D. M., Yorek, M. & Shasby, S. S. (1988) *Blood* **72,** 491–499.
- 21. Zick, Y. & Sagi-Eisenberg, R. (1990) *Biochemistry* **29,** 10240– 10245.
- 22. Schieven, G. L., Kirihara, J. M., Burg, D. L., Geahlen, R. L. & Ledbetter, J. A. (1993) *J. Biol. Chem.* **268,** 16688–16692.
- 23. Qin, S., Inazu, T. & Yamamura, H. (1995) *Biochem. J.* **308,** 347–352.
- 24. Hardwick, J. S. & Sefton, B. M. (1995) *Proc. Natl. Acad. Sci. USA* **92,** 4527–4531.
- 25. Liu, F. & Roth, R. A. (1994) *Biochem. Biophys. Res. Commun.* **200,** 1570–1577.
- 26. Mukai, H. & Ono, Y. (1994) *Biochem. Biophys. Res. Commun.* **199,** 897–904.
- 27. Konishi, H., Kuroda, S., Tanaka, M., Matsuzaki, H., Ono, Y., Kameyama, K., Haga, T. & Kikkawa, U. (1995) *Biochem. Biophys. Res. Commun.* **216,** 526–534.
- 28. Keranen, L. M., Dutil, E. M. & Newton, A. C. (1995) *Curr. Biol.* **5,** 1394–1403.
- 29. Tsutakawa, S. E., Medzihradszky, K. F., Flint, A. J., Burlingame, A. L. & Koshland, D. E., Jr. (1995) *J. Biol. Chem.* **270,** 26807– 26812.
- 30. Seger, R. & Krebs, E. G. (1995) *FASEB J.* **9,** 726–735.
- 31. Stempka, L., Girod, A., Muller, H. J., Rincke, G., Marks, F., Gschwendt, M. & Bossemeyer, D. (1997) *J. Biol. Chem.* **272,** 6805–6811.
- 32. Sundaresan, M., Yu, Z.-X., Ferrans, V. J., Irani, K. & Finkel, T. (1995) *Science* **270,** 296–299.
- 33. Meyer, M., Schreck, R. & Baeuerle, P. A. (1993) *EMBO J.* **12,** 2005–2015.
- 34. Stauble, B., Boscoboinik, D., Tasinato, A. & Azzi, A. (1994) *Eur. J. Biochem.* **226,** 393–402.